Matt Hewitt

“Maybe to start off, congratulations on the exploration sales. Given that you do have a few in the ecosystem at the moment, what are you seeing from a utilization standpoint?”

“First, obviously you announced several competitive wins across the portfolio of applications.”

“And like others, congratulations on the acquisition. You noted, and I think people understand, that there's a significant opportunity to grow BioLife products outside of the U.S. Obviously, just getting this started here, but as you look at it, what is the low-hanging fruit to really drive the growth of the U.S.?”

“Maybe first up, regarding the Merck enzyme, I'm just curious, historically those have been talked or discussed as being kind of $5 to $10 million in annual revenues.”

“Please proceed with your question. good afternoon and thanks for taking the questions obviously it's it's nice to hear we're starting to see some positive impact from the changes that we started to see last fall but maybe first up i was hoping we could dig in a little bit on the three large pharma customers that you…”